Trevi Therapeutics Lands $173 Million Funding Boost
Event summary
- Trevi Therapeutics completed a public offering of 13,340,000 shares at $13.00 per share.
- The offering, including the underwriters’ option, raised approximately $173 million in net proceeds.
- Morgan Stanley, Leerink Partners, Cantor, and Stifel acted as joint book-running managers, with Oppenheimer & Co. as lead manager.
- The offering was conducted under a shelf registration statement filed with the SEC on November 13, 2025.
The big picture
The successful offering underscores investor appetite for clinical-stage biopharmaceutical companies with differentiated therapies targeting significant unmet needs. Trevi's focus on chronic cough in IPF, ILD, and RCC represents a relatively underserved market, but the company faces the inherent risks associated with drug development and regulatory approval. The $173 million raise provides a buffer, but execution on clinical milestones will be critical to sustaining this valuation.
What we're watching
- Cash Runway
- The substantial capital infusion extends Trevi’s cash runway, likely enabling continued clinical development of Haduvio and supporting pre-commercialization activities, but the burn rate will be a key indicator of long-term viability.
- Clinical Trial Progress
- The success of Haduvio's development and eventual regulatory approval remains the primary driver of Trevi's valuation; progress in ongoing clinical trials will be crucial to maintaining investor confidence.
- Market Adoption
- Given the niche nature of IPF and RCC treatments, the pace at which physicians adopt Haduvio, if approved, will significantly impact revenue generation and the company's ability to achieve profitability.
Related topics